Gene targeting is a general method to mutate or replace genes at specific chromosomal sites in intact cells. The method relies on the production of a site-specific double-strand DNA break at the locus of interest, which is subsequently repaired by recombination with a homologous transgene. Precision BioSciences has developed a method for the production of """"""""custom"""""""" endonucleases capable of targeting such DNA breaks to unique chromosomal sites with genome-level specificity. One of these enzymes, EndoJAK2, was designed to recognize a site in the human JAK2 gene, which is associated with a wide range of myeloproliferative disorders. This proposal outlines a set of experiments to investigate the ability of the EndoJAK2 endonuclease to direct the modification of the chromosomal JAK2 gene in a human cell line. If successful, these experiments will not only promote the development of a novel cancer gene therapy but will validate a general method for in situ genome modification in human cells. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA134075-01
Application #
7480759
Study Section
Special Emphasis Panel (ZRG1-GGG-J (10))
Program Officer
Evans, Gregory
Project Start
2008-04-01
Project End
2009-09-30
Budget Start
2008-04-01
Budget End
2009-09-30
Support Year
1
Fiscal Year
2008
Total Cost
$100,000
Indirect Cost
Name
Precision Biosciences, Inc.
Department
Type
DUNS #
622558224
City
Durham
State
NC
Country
United States
Zip Code
27701